Biotech Mereo BioPharma pens $50M Ultragenyx deal for rare bone disease drug

Mereo BioPharma is teaming up with Ultragenyx to work on its rare genetic bone disease drug.

Worth $50 million upfront and with modest biobucks of up to $254 million on the table, the R&D collab and licensing deal focuses on setrusumab in osteogenesis imperfecta (OI), a rare genetic disorder marked by fragile bones and reduced bone mass resulting in bones that break easily, loose joints and weakened teeth.